Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
AstraZeneca
Federal Trade Commission
US Army
Accenture
Boehringer Ingelheim
Merck
Covington

Generated: November 16, 2018

DrugPatentWatch Database Preview

GABITRIL Drug Profile

« Back to Dashboard

Which patents cover Gabitril, and what generic alternatives are available?

Gabitril is a drug marketed by Cephalon and is included in one NDA.

The generic ingredient in GABITRIL is tiagabine hydrochloride. There are five drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the tiagabine hydrochloride profile page.

Drug patent expirations by year for GABITRIL
Synonyms for GABITRIL
(-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid
(-)-(R)-1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid hydrochloride
(-)-(R)-1-(4,4-Bis(3-methyl-2-thienyl)-3-butenyl)nipecotic acid, hydrochloride
(-)-(R)-1-[4,4-Bis(3- methyl-2-thienyl)-3-butenyl]nipecotic acid hydrochloride
(-)-(r)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(-)-(R)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid hydrochloride
(-)-(R)-1-[4,4-Bis(3-methyl-2-thienyl)-3butenyl]nipecotic acid hydrochloride
(3R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-buten-1-yl]-3-piperidinecarboxylic acid hydrochloride
(3R)-1-[4,4-Bis(3-methyl-2-thienyl)-3-butenyl]-3-piperidinecarboxylic Acid Hydrochloride
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]-3-carboxypiperidinium chloride
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]piperidine-3-carboxylic acid monohydrochloride
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-enyl]piperidine-3-carboxylic acid
(3R)-1-[4,4-bis(3-methyl-2-thienyl)but-3-enyl]piperidine-3-carboxylic acid hydrochloride
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid hydrochloride
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid hydrochloride
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-enyl]piperidine-3-carboxylic acid;hydrochloride
(R)-(-)-1-[4,4-bis(3-methyl-2-thienyl)-3-butenyl]nipecotic acid
(R)-1-(4,4-Bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid
(r)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl)piperidine-3-carboxylic acid hydrochloride
(R)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enyl)piperidine-3-carboxylic acid hydrochloride
(R)-1-[4,4-Bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid
(R)-1-[4,4-Bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid; hydrochloride
(r)-n-[4,4-bis(3-methyl-2-thienyl)but-3-en-1-yl]nipecotic acid
(R)-Tiagabine
(S)-1-(4,4-bis(3-methylthiophen-2-yl)but-3-enyl)piperidine-3-carboxylic acid
[3H]tiagabine
1-[4,4-Bis-(3-methyl-4,5-dihydro-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid
1-[4,4-Bis-(3-methyl-thiophen-2-yl)-but-3-enyl]-piperidine-3-carboxylic acid; hydrochloride
103T543
115103-54-3
145821-59-6
3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-buten-yl)-, hydrochloride, (R)-
3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, (R)-
3-Piperidinecarboxylic acid, 1-(4,4-bis(3-methyl-2-thienyl)-3-butenyl)-, hydrochloride, (R)-
4CH-019728
A-70569
A-70569-1
Abbott 70569.HCl
Abbott-70569
ABBOTT-70569-1
Abbott-70569.1
ABBOTT-70569.HCL
ABT 569
ABT-569
AC-7048
AC1L1TNE
AC1L3LR1
AC1Q5R43
AJ-45795
AK122370
AK155448
AKOS016011165
AKOS024258856
AN-31388
AN-9377
API0004405
API0009125
AX8154081
AX8154082
BDBM50039251
BDBM50368628
BG0438
BIDD:GT0018
C-21249
C07503
C20H25NO2S2
C20H25NO2S2.HCl
C20H26ClNO2S2
CAS-145821-59-6
CC-35052
CCG-100885
CEP-6671
CHEBI:85388
CHEBI:9586
CHEMBL1027
CHEMBL1695
CPD000469176
CS-2936
CS-2937
D02097
D08588
D0C1XB
D0ED7U
DB00906
DQH6T6D8OY
DR002100
DSSTox_CID_24218
DSSTox_GSID_44218
DSSTox_RID_80125
DTXSID2044218
DTXSID5023663
EN300-221591
EN300-222195
FT-0631075
FT-0675216
Gabatril
Gabitril (TN)
Gabitril hydrochloride
GTPL4685
GTPL4818
H03T543
HE298426
HSDB 7527
HY-B0696
HY-B0696A
J-008159
KB-209487
KB-308664
KS-00000H6B
KS-1217
LS-114651
LS-173258
MFCD07369025
MLS001401367
MolPort-006-069-142
MolPort-006-167-658
N-(4,4-di(3-methylthien-2-yl)but-3-enyl)nipecotic acid
NC00135
NCGC00164626-01
NCGC00164626-02
NN-301
NNC-05-0328
NO 050328
NO 328
NO 329
NO-05-0328
NO-328
NO-329
NO050328
NO050328 hydrochloride
NO050328;NO328;TGB
NO328
NO328 hydrochloride
PBJUNZJWGZTSKL-MRXNPFEDSA-N
s4661
s4675
SAM001246625
SCHEMBL34653
SCHEMBL41860
SMR000469176
ST2402069
TGB
TGB hydrochloride
Tiabex
Tiagabina
Tiagabina [INN-Spanish]
tiagabine
Tiagabine (hydrochloride)
Tiagabine (INN)
Tiagabine [INN:BAN]
Tiagabine [INN]
TIAGABINE HCl
Tiagabine hydrochloride
Tiagabine hydrochloride (USP)
Tiagabine hydrochloride [USAN:USP]
Tiagabine hydrochloride [USAN]
Tiagabine Hydrochloride 1.0 mg/ml in Methanol (as free base)
Tiagabine hydrochloride solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material
Tiagabine hydrochloride, >=98% (HPLC)
tiagabine monohydrochloride
Tiagabinehydrochloride
Tiagabinum
Tiagabinum [INN-Latin]
Tox21_112245
Tox21_112245_1
UNII-DQH6T6D8OY
UNII-Z80I64HMNP
VC30712
YUKARLAABCGMCN-PKLMIRHRSA-N
Z2216208631
Z80I64HMNP
ZINC3831531

US Patents and Regulatory Information for GABITRIL

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-005 Apr 16, 1999 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-003 Sep 30, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-007 Nov 29, 2005 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-004 Sep 30, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-001 Sep 30, 1997 AB RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-006 Nov 29, 2005 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-002 Sep 30, 1997 AB RX Yes No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Expired US Patents for GABITRIL

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-001 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-004 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-005 Apr 16, 1999 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-005 Apr 16, 1999 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-003 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-002 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Cephalon GABITRIL tiagabine hydrochloride TABLET;ORAL 020646-002 Sep 30, 1997 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for GABITRIL
Drugname Dosage Strength RLD Date
➤ Subscribe Tablets 12 mg and 16 mg ➤ Subscribe ➤ Sign Up
➤ Subscribe Tablets 2 mg and 4 mg ➤ Subscribe ➤ Sign Up

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Farmers Insurance
AstraZeneca
Federal Trade Commission
US Army
Accenture
Boehringer Ingelheim
Merck
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.